Baidu
map

三伏贴出新规,不备案不得开展,五种行为要退费

2018-07-12 羽兮 基层医师公社

有种冲动叫做三伏天必须要去贴三伏贴!每年这个季节,贴三伏贴都是各个医疗机构最热门的服务项目。但在今年可能会遭遇“降温”,已经有地方出台方案,三伏贴必须符合适应症才能贴,也只有这些人才能贴!

有种冲动叫做三伏天必须要去贴三伏贴!每年这个季节,贴三伏贴都是各个医疗机构最热门的服务项目。但在今年可能会遭遇“降温”,已经有地方出台方案,三伏贴必须符合适应症才能贴,也只有这些人才能贴!

近日,北京市中医管理局下发《2018年北京中医药“冬病夏治三伏贴”工作方案》(以下简称《方案》)。



该文件明确指出各医疗机构必须严格规范对穴位贴敷项目临床应用管理。今年开展三伏贴服务必须对症对人,每次收费限收30元。

1.限制人群,限制适应症,每疗程不得超过3次

《方案》对适宜人群和适应症提出精准要求:仅可对慢性呼吸系统疾病(支气管炎、支气管哮喘、过敏性鼻炎)及小儿、老年(60岁以上)体虚易感冒、反复咳喘(呼吸道感染)人群开展“冬病夏治穴位贴敷”。



同时按照规定,“冬病夏治穴位敷贴”项目每次收取30元治疗费。2018年三伏为40天,每10天为一个疗程,每疗程敷贴次数不得超过3次。

也就是说,除了对以上提到的几种适应症和适合三伏贴的人群开展服务外,其他行为都是超范围操作。铤而走险任性乱贴无论是对于医务人员还是患者自身,其安全性都很难保证。毕竟,三伏贴不是万能贴,什么病都能治,什么人群都适合。

2.方案印发前不符合要求,三伏贴费用全退!

据悉,该方案当地中医管理局于7月4日印发的,在此之前已经开展“三伏贴”服务的机构,如果不符合相关要求,须做退费处理。



在开展三伏贴服务医疗机构资质、敷贴制剂成分及审批、诊疗适应症及项目收费等方面,以下行为统归为不良行为,或将要求相关医疗机构直接退费:

(1)使用未经批准的三伏贴制剂

医疗机构不得使用未经市食品药品监督管理局批准配置或调剂使用的“冬病夏治三伏贴”院内制剂开展“冬病夏治三伏贴”服务。

(2)超出适用病症开展三伏贴服务

除规定的“冬病夏治穴位敷贴”项目适用病症外,其他病种不得套用“冬病夏治穴位敷贴”项目。

(3)使用不含中药成分的穴位贴

各医疗机构不得将以物理、化学方式制作(含“碱”“健”字号)、不含中药成分的穴贴(如红外贴、磁疗贴等)作为“三伏贴”使用,不得按照“冬病夏治穴位敷贴”项目收费。

(4)收取额外费用

除了“冬病夏治穴位敷贴”项目每次收取30元治疗费,各医疗机构不得再另外收取药品、材料等其他任何费用。不按照技术规范提供“冬病夏治三伏贴”服务的不得收费。

(5)未备案开展三伏贴服务

各医疗机构不经备案不得开展中医药“冬病夏治三伏贴”服务。

3.伏贴怎么贴?示范动作来了

文件做出规定,要求各医疗机构必须严格执行专家组制定的《2018年中医药冬病夏治穴位敷贴技术规范》中的敷贴穴位、操作方法为患者提供服务。具体怎么贴?贴哪里?看这里!

(1)常用穴位

根据“冬病夏治三伏贴”技术规范,建议腧穴如下。

选穴:辨证选取足太阳膀胱经的肺俞、心俞、膈俞,手太阴肺经的中府,经外奇穴定喘(均为双穴);督脉的大椎,任脉膻中(均为单穴)。

推荐首选大椎、膻中、肺俞、膈俞,或肺俞、心俞、膈俞。选用大椎穴时可配膻中穴。心功能不全者可选用心俞,脾肾阳虚者可选用脾俞、肾俞。





每次选用3~4个腧穴(6个贴敷点),轮流选用。

(2)敷贴方法

患者取正坐位,充分暴露贴敷部位。贴敷背部时上身微前倾,双臂自然放松垂于身体两侧。

先用干毛巾或纸巾擦去汗液,再用75%的酒精消毒贴敷局部皮肤(面积要大于贴敷面积),待皮肤干燥后,将贴敷药物放在选取的腧穴上,按压固定即可。

(3)敷贴时间

传统穴位贴敷时间为农历三伏(初、中、末伏。今年的中伏为20天,按4个伏计)每伏的第一天开始。目前每伏的任何一天均可,以晴天的10:00—17:00为佳。

成人每伏连贴3次,每天一次,每次贴敷6—8小时。每伏间隔7天。儿童每伏各贴3次,每次间隔3天,根据年龄每次贴敷1—4小时。



以下附全文:

2018年北京中医药“冬病夏治三伏贴”

工作方案

2018年中医药“冬病夏治三伏贴”时间:初伏(7月17~26日);中伏(7月27日~8月15日);末伏(8月16日~8月25日)。为进一步加强对中医药“冬病夏治三伏贴”工作的管理,规范中医药“冬病夏治三伏贴”行为,改善中医药“冬病夏治三伏贴”服务,更好地满足广大患者的需求,现就2018年中医药“冬病夏治三伏贴”工作制定如下方案(以下简称“方案”)。

一、进一步强化对“三伏贴”工作的全过程管理。

(一)医疗机构要严格按照《全国医疗服务价格项目规范》的要求执行,提供“冬病夏治三伏贴”服务必须使用经北京市食品药品监督管理局批准的制剂。

同时,经市食品药品监督管理局批准,在全市调配使用首都医科大学附属北京中医医院的院内制剂“温阳化痰穴贴”(批准文号:京药制字Z20110007)、中国中医科学院广安门医院的院内制剂“消喘膏”(批准文号:京药制字Z20063222)。

(二)各医疗机构要严格对“冬病夏治穴位贴敷”项目的临床应用管理,仅可对慢性呼吸系统疾病(支气管炎、支气管哮喘、过敏性鼻炎)及小儿、老年(60岁以上)体虚易感冒、反复咳喘(呼吸道感染)人群开展“冬病夏治穴位贴敷”项目。

(三)各医疗机构要严格对“冬病夏治三伏贴”服务的收费管理。各医疗机构提供中医药“冬病夏治三伏贴”服务只可收取1次普通门诊医事服务费,在社区卫生服务机构进行贴敷的患者可免收医事服务费。按照市发展改革委《关于规范调整床位费等医疗服务价格项目的通知》(京发改〔2017〕323号)要求,“冬病夏治穴位贴敷”项目每次收取30元治疗费。2018年三伏为40天,每10天为一个疗程,每疗程贴敷次数不得超过3次。

(四)各医疗机构要严格执行我局组织专家制定的《2018年中医药冬病夏治穴位贴敷技术规范》中的贴敷穴位、操作方法,认真做好中医药“冬病夏治三伏贴”服务记录,掌握禁忌症与常见不良反应处置方法,医疗机构应建立知情同意制度,规范开展服务。

我局将委托北京针灸学会对基层社区卫生服务机构提供业务指导、服务支援和人员培训。各区卫生计生委选派基层社区卫生服务机构骨干参加我局组织的中医药冬病夏治穴位贴敷培训,并将其作为区级师资,及时组织好辖区内医疗机构的人员培训。北京针灸学会将根据各区培训需求,组织专家支援或直接承担各区的培训工作。

(五)各区卫生计生委要加强对中医药“冬病夏治三伏贴”的宣传。拟开展中医药“冬病夏治三伏贴”的医疗机构,向所在辖区的卫生计生委报送“冬病夏治三伏贴工作汇总表”,各区卫生计生委审核、汇总后,报我局审定备案,我局将在相关媒体进行公告。

同时,各区要重点针对“冬病夏治三伏贴”的适用病证介绍贴敷的适应症、禁忌症、注意事项等知识,向社区居民免费发放我局统一编制的“冬病夏治穴位贴敷法(十问)”宣传资料,采取多种方式向社区居民公布贴敷服务站点。7月17日全市全面启动贴敷工作,每个区至少选择1个社区开展“冬病夏治三伏贴”服务社区百姓启动宣传活动,正确引导社区居民在社区接受“冬病夏治三伏贴”服务,防止群众盲目贴敷。

二、进一步加大对“冬病夏治三伏贴”服务不良行为的监管。

(一)医疗机构不得使用未经市食品药品监督管理局批准配制或调剂使用的“冬病夏治三伏贴”院内制剂开展“冬病夏治三伏贴”服务。

(二)除规定的“冬病夏治穴位贴敷”项目适用病证外,其他病种不得套用“冬病夏治穴位贴敷”项目。

(三)各医疗机构不得将以物理、化学方式制作(含“械”“健”字号)、不含中药成分的穴贴(如红外贴、磁疗贴等)作为“三伏贴”使用,不得按照“冬病夏治穴位贴敷”项目收费。

(四)除了“冬病夏治穴位贴敷”项目每次收取30元治疗费,各医疗机构不得再另外收取药品、材料等其他任何费用。不按照技术规范提供“冬病夏治三伏贴”服务的不得收费。

(五)各医疗机构不经备案不得开展中医药“冬病夏治三伏贴”服务。

三、工作要求

(一)组织工作落地。各区卫生计生委要加强组织领导,明确职责,认真做好此次活动的组织和落实工作。要组织好社区卫生服务机构开展三伏贴服务进机关、进乡村活动,把“冬病夏治三伏贴”作为健康乡村服务百姓、中医治未病工程、中医健康养老身边工程、名中医身边工程的一项重要工作。各医疗机构要把开展“冬病夏治三伏贴”工作列入本单位的重要工作日程,严格落实本方案要求,确保中医药“冬病夏治三伏贴”工作顺利开展。

(二)宣传动员落准。我局将制作宣传材料发放给各区卫生计生委。各区卫生计生委要组织协调相关部门,及时将宣传品张贴到本辖区的社区、街道、乡村,畅通群众的选择渠道。各医疗机构要结合本单位实际,将本方案的主要内容多途径提供给广大群众,指导群众科学选用服务。

(三)督导检查落细。各区卫生计生委要按照本方案确定的工作进度,细化工作计划,完善工作方案,保质保量地完成各项工作任务;要加强对基层社区卫生机构服务行为的指导,及时发现和解决问题;要加强监督管理,及时处理违反规定的机构;要加强信息沟通,及时将工作开展情况反馈给我局。

在本方案印发前已经开展预约登记并收取费用的医疗机构,不符合本方案规范要求的,要按照本方案确定的标准做好退费工作。

(四)信息报送落实。各区卫生计生委于2018年7月11日前,将工作方案、冬病夏治三伏贴工作汇总表(附件2)、冬病夏治三伏贴培训需求表(附件3)报送至我局。我局将汇总信息,协调市发展改革委、市人力社保局和市食品药品监管局等相关部门进行备案,并将相关信息在北京中医药信息网进行公示。

各区卫生计生委组织各有关单位如实填写2018年“冬病夏治三伏贴登记表”(附件4),完成各区三伏贴工作总结(包括文字、图片、影像资料),于2018年9月25日前,以区为单位报送至市中医局医政(基层卫生)处和北京针灸学会。

(五)评价工作落稳。各医疗机构要做好中医药“冬病夏治三伏贴”情况监测、回顾调查及总结,鼓励社区医生参与做好中医药“冬病夏治三伏贴”回顾性调查,定期回访患者使用情况,开展中医药“冬病夏治三伏贴”数据的统计及疗效研究。

各医疗机构如发现贴敷的不良反应,应及时填写“冬病夏治三伏贴”不良反应报告表(附件5),通过辖区卫生计生委报告至我局医政(基层卫生)处和北京针灸学会,同时报告给市食品药品监管局。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1574362, encodeId=b8d015e436297, content=<a href='/topic/show?id=3c2c586e23f' target=_blank style='color:#2F92EE;'>#新规#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58672, encryptionId=3c2c586e23f, topicName=新规)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2ca16016783, createdName=xsm923, createdTime=Fri Jul 13 15:56:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590879, encodeId=720d15908e9ef, content=<a href='/topic/show?id=9a09195802c' target=_blank style='color:#2F92EE;'>#三伏贴#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19580, encryptionId=9a09195802c, topicName=三伏贴)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e2917881436, createdName=freve, createdTime=Fri Jul 13 15:56:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590950, encodeId=726f1590950ed, content=<a href='/topic/show?id=f175424e6fe' target=_blank style='color:#2F92EE;'>#备案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42476, encryptionId=f175424e6fe, topicName=备案)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41f217885803, createdName=cenghis, createdTime=Fri Jul 13 15:56:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331033, encodeId=7cf4331033f1, content=逐步规范中医药管理, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Thu Jul 12 09:18:50 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331005, encodeId=f12f331005e3, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Jul 12 06:40:02 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=330985, encodeId=5d0c33098553, content=学习学习再学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Thu Jul 12 05:51:32 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=330976, encodeId=92333309e618, content=学习学习.了解了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Thu Jul 12 05:13:04 CST 2018, time=2018-07-12, status=1, ipAttribution=)]
    2018-07-13 xsm923
  2. [GetPortalCommentsPageByObjectIdResponse(id=1574362, encodeId=b8d015e436297, content=<a href='/topic/show?id=3c2c586e23f' target=_blank style='color:#2F92EE;'>#新规#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58672, encryptionId=3c2c586e23f, topicName=新规)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2ca16016783, createdName=xsm923, createdTime=Fri Jul 13 15:56:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590879, encodeId=720d15908e9ef, content=<a href='/topic/show?id=9a09195802c' target=_blank style='color:#2F92EE;'>#三伏贴#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19580, encryptionId=9a09195802c, topicName=三伏贴)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e2917881436, createdName=freve, createdTime=Fri Jul 13 15:56:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590950, encodeId=726f1590950ed, content=<a href='/topic/show?id=f175424e6fe' target=_blank style='color:#2F92EE;'>#备案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42476, encryptionId=f175424e6fe, topicName=备案)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41f217885803, createdName=cenghis, createdTime=Fri Jul 13 15:56:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331033, encodeId=7cf4331033f1, content=逐步规范中医药管理, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Thu Jul 12 09:18:50 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331005, encodeId=f12f331005e3, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Jul 12 06:40:02 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=330985, encodeId=5d0c33098553, content=学习学习再学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Thu Jul 12 05:51:32 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=330976, encodeId=92333309e618, content=学习学习.了解了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Thu Jul 12 05:13:04 CST 2018, time=2018-07-12, status=1, ipAttribution=)]
    2018-07-13 freve
  3. [GetPortalCommentsPageByObjectIdResponse(id=1574362, encodeId=b8d015e436297, content=<a href='/topic/show?id=3c2c586e23f' target=_blank style='color:#2F92EE;'>#新规#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58672, encryptionId=3c2c586e23f, topicName=新规)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2ca16016783, createdName=xsm923, createdTime=Fri Jul 13 15:56:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590879, encodeId=720d15908e9ef, content=<a href='/topic/show?id=9a09195802c' target=_blank style='color:#2F92EE;'>#三伏贴#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19580, encryptionId=9a09195802c, topicName=三伏贴)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e2917881436, createdName=freve, createdTime=Fri Jul 13 15:56:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590950, encodeId=726f1590950ed, content=<a href='/topic/show?id=f175424e6fe' target=_blank style='color:#2F92EE;'>#备案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42476, encryptionId=f175424e6fe, topicName=备案)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41f217885803, createdName=cenghis, createdTime=Fri Jul 13 15:56:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331033, encodeId=7cf4331033f1, content=逐步规范中医药管理, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Thu Jul 12 09:18:50 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331005, encodeId=f12f331005e3, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Jul 12 06:40:02 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=330985, encodeId=5d0c33098553, content=学习学习再学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Thu Jul 12 05:51:32 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=330976, encodeId=92333309e618, content=学习学习.了解了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Thu Jul 12 05:13:04 CST 2018, time=2018-07-12, status=1, ipAttribution=)]
    2018-07-13 cenghis
  4. [GetPortalCommentsPageByObjectIdResponse(id=1574362, encodeId=b8d015e436297, content=<a href='/topic/show?id=3c2c586e23f' target=_blank style='color:#2F92EE;'>#新规#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58672, encryptionId=3c2c586e23f, topicName=新规)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2ca16016783, createdName=xsm923, createdTime=Fri Jul 13 15:56:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590879, encodeId=720d15908e9ef, content=<a href='/topic/show?id=9a09195802c' target=_blank style='color:#2F92EE;'>#三伏贴#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19580, encryptionId=9a09195802c, topicName=三伏贴)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e2917881436, createdName=freve, createdTime=Fri Jul 13 15:56:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590950, encodeId=726f1590950ed, content=<a href='/topic/show?id=f175424e6fe' target=_blank style='color:#2F92EE;'>#备案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42476, encryptionId=f175424e6fe, topicName=备案)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41f217885803, createdName=cenghis, createdTime=Fri Jul 13 15:56:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331033, encodeId=7cf4331033f1, content=逐步规范中医药管理, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Thu Jul 12 09:18:50 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331005, encodeId=f12f331005e3, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Jul 12 06:40:02 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=330985, encodeId=5d0c33098553, content=学习学习再学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Thu Jul 12 05:51:32 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=330976, encodeId=92333309e618, content=学习学习.了解了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Thu Jul 12 05:13:04 CST 2018, time=2018-07-12, status=1, ipAttribution=)]
    2018-07-12 lyh994

    逐步规范中医药管理

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1574362, encodeId=b8d015e436297, content=<a href='/topic/show?id=3c2c586e23f' target=_blank style='color:#2F92EE;'>#新规#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58672, encryptionId=3c2c586e23f, topicName=新规)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2ca16016783, createdName=xsm923, createdTime=Fri Jul 13 15:56:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590879, encodeId=720d15908e9ef, content=<a href='/topic/show?id=9a09195802c' target=_blank style='color:#2F92EE;'>#三伏贴#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19580, encryptionId=9a09195802c, topicName=三伏贴)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e2917881436, createdName=freve, createdTime=Fri Jul 13 15:56:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590950, encodeId=726f1590950ed, content=<a href='/topic/show?id=f175424e6fe' target=_blank style='color:#2F92EE;'>#备案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42476, encryptionId=f175424e6fe, topicName=备案)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41f217885803, createdName=cenghis, createdTime=Fri Jul 13 15:56:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331033, encodeId=7cf4331033f1, content=逐步规范中医药管理, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Thu Jul 12 09:18:50 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331005, encodeId=f12f331005e3, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Jul 12 06:40:02 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=330985, encodeId=5d0c33098553, content=学习学习再学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Thu Jul 12 05:51:32 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=330976, encodeId=92333309e618, content=学习学习.了解了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Thu Jul 12 05:13:04 CST 2018, time=2018-07-12, status=1, ipAttribution=)]
    2018-07-12 1209e435m98(暂无昵称)

    学习了.谢谢分享

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1574362, encodeId=b8d015e436297, content=<a href='/topic/show?id=3c2c586e23f' target=_blank style='color:#2F92EE;'>#新规#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58672, encryptionId=3c2c586e23f, topicName=新规)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2ca16016783, createdName=xsm923, createdTime=Fri Jul 13 15:56:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590879, encodeId=720d15908e9ef, content=<a href='/topic/show?id=9a09195802c' target=_blank style='color:#2F92EE;'>#三伏贴#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19580, encryptionId=9a09195802c, topicName=三伏贴)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e2917881436, createdName=freve, createdTime=Fri Jul 13 15:56:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590950, encodeId=726f1590950ed, content=<a href='/topic/show?id=f175424e6fe' target=_blank style='color:#2F92EE;'>#备案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42476, encryptionId=f175424e6fe, topicName=备案)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41f217885803, createdName=cenghis, createdTime=Fri Jul 13 15:56:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331033, encodeId=7cf4331033f1, content=逐步规范中医药管理, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Thu Jul 12 09:18:50 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331005, encodeId=f12f331005e3, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Jul 12 06:40:02 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=330985, encodeId=5d0c33098553, content=学习学习再学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Thu Jul 12 05:51:32 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=330976, encodeId=92333309e618, content=学习学习.了解了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Thu Jul 12 05:13:04 CST 2018, time=2018-07-12, status=1, ipAttribution=)]
    2018-07-12 yjs木玉

    学习学习再学习

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1574362, encodeId=b8d015e436297, content=<a href='/topic/show?id=3c2c586e23f' target=_blank style='color:#2F92EE;'>#新规#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58672, encryptionId=3c2c586e23f, topicName=新规)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2ca16016783, createdName=xsm923, createdTime=Fri Jul 13 15:56:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590879, encodeId=720d15908e9ef, content=<a href='/topic/show?id=9a09195802c' target=_blank style='color:#2F92EE;'>#三伏贴#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19580, encryptionId=9a09195802c, topicName=三伏贴)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e2917881436, createdName=freve, createdTime=Fri Jul 13 15:56:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590950, encodeId=726f1590950ed, content=<a href='/topic/show?id=f175424e6fe' target=_blank style='color:#2F92EE;'>#备案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42476, encryptionId=f175424e6fe, topicName=备案)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41f217885803, createdName=cenghis, createdTime=Fri Jul 13 15:56:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331033, encodeId=7cf4331033f1, content=逐步规范中医药管理, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Thu Jul 12 09:18:50 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331005, encodeId=f12f331005e3, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Jul 12 06:40:02 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=330985, encodeId=5d0c33098553, content=学习学习再学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Thu Jul 12 05:51:32 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=330976, encodeId=92333309e618, content=学习学习.了解了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Thu Jul 12 05:13:04 CST 2018, time=2018-07-12, status=1, ipAttribution=)]
    2018-07-12 1dd8c52fm63(暂无匿称)

    学习学习.了解了解

    0

相关资讯

旗帜鲜明地反对滥用三伏贴

三伏贴已经红火了好几年了 就三伏贴问题 大家能见到两大帮派 一个是以各中医院诊所为代表 鼓吹冬病夏治的好处 一个是各种中医黑们 因为黑所以黑 说三伏贴是安慰剂

Baidu
map
Baidu
map
Baidu
map